Skip to main content

Table 2 Change in phosphorylated AKT (pS473_AKT) post-treatment with lapatinib and/or trastuzumab in HER2-positive breast tumours18

From: Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL

Patient no. Treatment regimen pS473_AKT  
Fold change post-treatment pCR
21 Lapatinib 1.1 No
42 Lapatinib 1.3 No
3 Lapatinib 1.0 No
45 Lapatinib 1.5 No
85 Lapatinib 2.2 Yes
185 Lapatinib 1.6 No
369 Lapatinib 1.8 Yes
7 Lapatinib 1.7 No
8 Lapatinib 3.7 No
204 Lapatinib 1.3 No
491 Lapatinib 0.7 No
504 Lapatinib 1.1 Yes
507 Lapatinib 0.7 Yes
81 Trastuzumab 0.5 Yes
82 Trastuzumab 1.0 Yes
321 Trastuzumab 0.4 Yes
365 Trastuzumab 5.0 Yes
24 Trastuzumab 4.1 Yes
364 Trastuzumab 0.9 No
5 Trastuzumab 0.6 Yes
31 Trastuzumab 0.9 Yes
84 Trastuzumab 0.6 No
202 Trastuzumab 0.5 No
367 Trastuzumab 0.4 Yes
6 Trastuzumab 0.6 No
39 Trastuzumab 0.3 No
193 Trastuzumab 3.9 No
412 Trastuzumab 3.7 Yes
442 Trastuzumab 0.2 No
506 Trastuzumab 1.2 Yes
23 Trast + Lapatinib 4.1 Yes
44 Trast + Lapatinib 9.0 No
30 Trast + Lapatinib 2.7 Yes
363 Trast + Lapatinib 0.5 Yes
303 Trast + Lapatinib 0.7 Yes
88 Trast + Lapatinib 1.2 Yes
221 Trast + Lapatinib 1.1 Yes
373 Trast + Lapatinib 0.9 Yes
501 Trast + Lapatinib 1.3 Yes
  1. Tumours with a decrease in pS473_AKT (≤0.8) are highlighted in bold